Is Propionic acid a suitable model for autism?

Abstract

Autism Spectrum Disorder (ASD) is defined as different degrees of disability in social interaction, stereotyped behavior, and altered motor and sensory perception. Many scientific research are concerned with making and developing animal models of autism to figure out the appropriate correlation between behavioural changes and the pathology of brain tissue to help in clinical trials of effective therapeutic formulations. Propionic acid can be present inside the cells as metabolite in a normal state and present in high amount in the gut due to some digestive disorders or alteration in gut microbiota. Moreover, it is considered an artificial food additive. Lately, propionic acid has become a controversy model. This review assessment demonstrates a complete picture and all the available information is needed to be known about the mechanism of action of the induced autistic model. It discusses the different methods explains the pathophysiology, and various treatment modalities were tried in the propionic induced animal model. It also enlists the developmental and behavioral aspects of the model animals

Lotusine ameliorates propionic acid‐induced autism spectrum disorder‐like behavior in mice by activating D1 dopamine receptor in medial prefrontal cortex

“…Propionic acid (PPA) is a short‐chain fatty acid thought to be associated with the development of ASD (Shultz & MacFabe, 2014). PPA administration in rats caused pathophysiological and clinical features similar to those seen in ASD patients (Ali et al, 2022; Khera et al, 2022; Sahin et al, 2022). Therefore, the PPA model serves as valid animal model to study the underlying neurobiology of ASD.…”

“…PPA administration in rats caused pathophysiological and clinical features similar to those seen in ASD patients (Ali et al, 2022;Khera et al, 2022;Sahin et al, 2022). Therefore, the PPA model serves as valid animal model to study the underlying neurobiology of ASD.…”

“…The ICV injection of PPA in mice was utilized to induce ASD-like behavior. This approach was previously employed in a rat model to investigate ASD pathogenesis (Ali et al, 2022). However, prior to our study, the potential of ICV-PPA administration to induce ASD-like behavior in mice remained uninvestigated.…”